|
Clinical and pathological characteristics of the 77 patients receiving radiotherapy, with or without the development of local recurrence |
|||
| All |
LR+RT+ |
LR-RT+ |
|
|
|
|||
| Time to local recurrence, months |
n = 30 |
n = 47 |
|
|
|
|||
| Median |
|||
| Range |
50 |
- |
|
| Follow-up, months |
8–149 |
- |
|
| Median |
|||
| Range |
- |
85 |
|
| Tamoxifen |
- |
62–231 |
|
| Chemotherapy |
6 |
1 |
|
| Tamoxifen and chemotherapy |
0 |
0 |
|
| No adjuvant treatment |
0 |
0 |
|
| 24 |
46 |
||
|
|
|||
| Inclusion 1 and 2 |
Inclusion 1 |
Inclusion 2 |
Inclusion 1 |
|
|
|||
| Menopause |
|||
| Pre |
12 |
5 |
13 |
| Post |
7 |
1 |
33 |
| Not available |
0 |
5 |
1 |
| Age at operation, years |
|||
| Median |
48 |
47 |
57 |
| Range |
27–63 |
34–73 |
33–73 |
| Size, millimeters |
|||
| Median |
14 |
15 |
15 |
| Range |
2–32 |
10–20 |
4–22 |
| Not available |
0 |
2a |
0 |
| Grade |
|||
| 1 |
3 |
3 |
22 |
| 2 |
8 |
6 |
13 |
| 3 |
7 |
1 |
10 |
| Not available |
1 |
1 |
2 |
| Estrogen receptor |
|||
| Positive |
9 |
11 |
42 |
| Negative |
10 |
0 |
5 |
| Progesterone receptor |
|||
| Positive |
5 |
9 |
31 |
| Negative |
13 |
2 |
11 |
| Not available |
1 |
0 |
5 |
| Health care region |
|||
| South |
8 |
2 |
30 |
| West |
2 |
0 |
9 |
| South-East |
0 |
9 |
0 |
| Stockholm |
9 |
0 |
8 |
|
aOne T1 and one T2. LR-RT+ = no local recurrence after radiotherapy; LR+RT+ = local recurrence developed after radiotherapy. | |||
Niméus-Malmström et al. Breast Cancer Research 2008 10:R34 doi:10.1186/bcr1997 |
|||